fibromyalgia
FIBROMYALGIA

Fibromyalgia is a clinical syndrome wherein the patient experiences generalized pain and fatigue that cannot be explained by the presence of any other disorder.
It is often considered to be psychosomatic or psychogenic in nature.
It is found in approximately 2% of the population and the prevalence increases with age, most common in women 20-55 year of age

Patient Education

  • Critical in the optimal management of FM
  • Goal is to help the patient understand & manage the symptoms optimally, reduce dependence on the medical system & work effectively w/in the system
  • Provide patient & family w/ information about FM, diagnosis & all treatment options
  • It should be emphasized that FM is a real disease & is not a deforming or a deteriorating disorder
    • Great majority of patients have normal & active lives
  • Emphasize the role of stress & mood disorder, encourage FM patients to learn simple relaxation techniques & to consider formal stress-reduction programs
  • Reinforce the importance of proper sleep hygiene
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 6 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 3 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.